Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 14/20 | 0.39 |
| ▸ | CASP7 | P55210 | 13/20 | 0.39 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136270 | 0.91 | BACE1 (0.38) | KCNH2HRH3CASP3CASP7CASP9 | |
| SCHEMBL4136050 | 0.91 | CASP3 (0.39) | KCNH2HRH3CASP3CASP7CASP9 | |
| SCHEMBL4143358 | 0.85 | USP30 (0.43) | USP30KCNH2HRH3DRD3PTGS2 | |
| SCHEMBL4144558 | 0.82 | MCHR1 (0.41) | KCNH2HRH3 | |
| SCHEMBL4133535 | 0.82 | HRH3 (0.43) | KCNH2HRH3 | |
| SCHEMBL4139555 | 0.79 | GPR84 (0.40) | USP30KCNH2HRH3 | |
| SCHEMBL4134993 | 0.79 | FAAH (0.38) | — | |
| SCHEMBL4144821 | 0.78 | USP30 (0.43) | USP30HRH3DRD3PTGS2 | |
| SCHEMBL4142661 | 0.78 | USP30 (0.43) | USP30HRH3DRD3PTGS2 | |
| SCHEMBL4140906 | 0.78 | USP30 (0.43) | USP30HRH3DRD3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | USP30 3191/4885KCNH2 657/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.